Disclosed herein is an attenuated Acinetobacter baumannii comprising an expression vector comprising a nucleic acid encoding the ABUW_1645 protein or a variant thereof. Disclosed herein are methods of treating or preventing colonization, infection, or disease by an Acinetobacter baumannii microbe, the method comprising administering a clinically effective dose of the attenuated Acinetobacter baumannii to a subject in need thereof, wherein the attenuated Acinetobacter baumannii comprises an expression vector expressing the ABUW_1645 protein or variants thereof.

Provided herein are glycosylated ComP proteins, fragments and fusion proteins thereof, and methods of making, for example, for use in the production of conjugate vaccines. Also provided herein are conjugate vaccines against diseases including bacterial diseases.

Mutants of Gram-negative bacteria having outer membranes comprising modified OrbA nanopores absent an N-terminal plug domain are disclosed. The modified OrbA nanopores confer the outer membrane of the bacteria with enhanced permeability. The mutants of Gram-negative bacteria optionally comprise efflux-deficient efflux pumps. The mutants may be used, for example, in a screening method for identifying a compound having an anti-bacterial activity.

The present invention provides specific peptide biomarkers and sets of peptide biomarkers for use in methods of detecting or identifying bacterial biomarkers in a sample, wherein said bacterial biomarkers can be used to detect Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Escherichia coli, and/or Moraxella catarrhalis in a sample. Kits and diagnostic methods are also provided.

The present invention discloses a Acinetobacter baumannii immunogenic protein and its composition and application. This invention provides a protein, comprising 39 amino acids of the N-terminal -helix part of the Ata protein transport functional domain of Acinetobacter baumannii and an adjuvant protein; amino acid sequence of said 39 amino acids of the N-terminal -helix part of the Ata protein transport functional domain of Acinetobacter baumannii is shown as the 127.sup.th-165.sup.th amino acid residues of SEQ ID NO:2. In present invention the 39 amino acids of the N-terminal -helix part of surface protein Ata (Acinetobacter trimeric autotransporter) of Acinetobacter baumannii, was took to fuse with CTB, and express in BL21. The protein was purified by a nickel column, and used to intraperitoneally immunize mouses by 2.5 g/mouse. Its immunogenicity and immunoprotection was verified through the animal experiments, which proves it has a good effect of anti-infection of Acinetobacter baumannii.

The present invention relates to proteins derived from Acinetobacter baumanii, nucleic acids encoding the proteins, antibodies specific for the proteins as well as methods of therapy, prophylaxis, and diagnosis that utilise the proteins, nucleic acids, and antibodies.

The present invention relates to the field of immunogenic compositions and vaccines and the use of such compositions in medicine. More particularly, it relates to immunogenic fragments of UspA2 comprising an epitope and immunogenic compositions and vaccines comprising said fragments, for use in preventing or treating an infection, disease or condition caused by heterologous strain(s) of Moraxella catarrhalis. The invention further relates to immunogenic compositions and vaccines comprising an immunogenic fragment wherein said fragment comprises an epitope with cross-bactericidal activity.

The invention provided a method for preparing a bacterial polysaccharide-modified recombinant fusion protein and use of the bacterial polysaccharide-modified recombinant fusion protein. The method comprises: co-expressing a recombinant fusion protein and the Neisseria meningitidis O-oligosaccharyltransferase PglL in an O-antigen ligase gene-defective bacterium, and linking a polysaccharides endogenous or exogenous for the bacterium to the recombinant fusion protein by the O-oligosaccharyltransferase PglL, to obtain the bacterial polysaccharide-modified recombinant fusion protein. The protein can be used for preparing antibodies against bacterial polysaccharides and vaccines.

The present invention relates to compositions comprising Moraxella catarrhalis (M. catarrhalis) Ubiquitous surface protein A2 (UspA2). More particularly, the present application relates to UspA2 protein constructs and immunogenic compositions comprising the constructs, vaccines comprising such immunogenic compositions and therapeutic uses of the same. The invention further relates to compositions comprising UspA2 in combination with at least one antigen from Haemophilus influenzae, immunogenic compositions comprising the antigens, vaccines comprising such immunogenic compositions and therapeutic uses of the same.

The present disclosure relates to surface proteins of Moraxella catarrhalis and their ability to interact with epithelial cells via cell-associated fibronectin and laminin, and also to their ability to inhibit the complement system. These surface proteins are useful in the preparation of vaccines. The present disclosure also provides peptides interacting with fibronectin, laminin and the complement system.